SYDNEY, Aug. 12 /PRNewswire-FirstCall/ -- ResMed, Inc. (NYSE: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)
As advised in the Company's 6 August announcement:
Due to the difference in market practice between the NYSE and ASX, ResMed applied for and has been granted a waiver of rules 13.9.4 and 13.9.9 of the ASX Settlement Operating Rules, allowing it to defer the processing of conversions (transmutations) between its Common Stock and CDI registers that are lodged in the period from and including 12 August 2010 up to and including 31 August 2010. Therefore, no conversions (transmutations) will be processed during this time. Processing of conversions will re-commence on 1 September 2010.
ResMed is a leading developer, manufacturer and distributor of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.
Further information can be obtained by contacting Constance Bienfait at ResMed, Inc., San Diego, on (+ 1 858-836-5971), or Brett Sandercock at ResMed Limited, Sydney, on (+61 2) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.
|SOURCE ResMed, Inc.|
Copyright©2010 PR Newswire.
All rights reserved